-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A new study published in Nature Cancer by researchers at the University of North Carolina's Lineberger Comprehensive Cancer Center found that CAR-T cells targeting neuroglycoside GD2 successfully eliminated retinal styrooma cells without damaging the eyesight of mice when combined with local releases of IL-15 and injectable hydrogels.
source: Nature Cancer Retinoblastoma (RB) is a rare malignant tumor that occurs in infants under 3 years of age and is caused by mutations in the double allied gene of the retinoblastoma gene (RB1).
that although the cancer can be cured in a timely manner at an early stage, about 5% of cases can still lose vision.
clinical needs for effective treatment of tumors and the ability to maintain vision in children have not been met.
GD2 is expressed in human retinal syringe tumors, but this substance is not expressed in normal human retina (below).
Although GD2 CAR-T has good tolerance and clinical benefits in some neuroblastoma patients (neuroblastoma is an embryonic tumor that can develop rapidly and has certain genetic characteristics of retinal scleoma), it is not clear whether targeting GD2 can safely eliminate intraocular tumors.
Source: Nature Cancer To test the safety and benefits of targeting GD2, researchers injected GD2 CAR-T into the retina of a mouse model of a retinal symacyte heterogeneous transplant, showing that tumor development was delayed but failed to eliminate the tumor.
the researchers then built CAR-T cells that secrete IL-15, a cytokine that enhances T-cell proliferation, activation, and survival.
results showed that adding IL-15 did not cause retinal scleroblastoma in mice treated with CD19 CAR-T to subside, but GD2 CAR-T, which expressed IL-15, had significantly improved anti-tumor effects, with 60 percent of the treated mice remaining tumor-free until the 70th day.
GD2. CAR.15 Anti-tumor effects were significantly enhanced (Source: Nature Cancer) In order to enhance the durability of CAR-T cells in tumors, the researchers chose the shell polysaccharine-polyglycol (PEG) thermal hydrogel as the best injectable hydrogel to deliver CAR-T in the eye.
T cells encapsulated in hydrogels remain active, released from the gel inside and out within 1 week, and retain cytotoxicity.
This hydrogel can significantly improve the anti-tumor effect of GD2 CAR-T, after injecting hydrogel containing CAR-T cells containing IL-15 into the retina of mice, not only can fully control tumor growth and prevent tumor recurrence, but also improve the structural recovery of the retina.
injectable hydrogels can further improve the treatment of GD2 CAR.15-T and prevent tumor recurrence (Source: Nature Cancer) This gel encapsulation therapy is currently being clinically tested in children with neuroblastoma. Professor Barbara Savoldo,
co-author of the paper, said: "We hope to be able to test the safety of gel injections in clinical trials in children's retinal scleroblastoma and, if safe, to continue to study the effects of this method on tumor reduction or elimination.
" References: 1, Wang, K., Chen, Y., Ahn, S. et al. GD2-specific CAR T cells encapsulated in an injectable hydrogel control retinoblastoma and preserve vision. Nature Cancer (2020) 2 s Dimaras, H., Corson, T., Cobrinik, D. et al. Retinoblastoma. Nature Reviews Disease Primers (2015) 3 s therapy using immune system cells preserves in mice implanted with rare eye cancer (Source: UNC Lineberger)